Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
Charles River Laboratories (NYSE: CRL) and CEBINA GmbH have announced a strategic collaboration within the DanubeNeuro acceleration program. This initiative aims to identify and advance pioneering academic research projects in the field of neurodegeneration. The collaboration will leverage CEBINA's experience in acceleration programs and Charles River's expertise in drug discovery and development for central nervous system (CNS) disorders.
The partnership seeks to address the growing global challenge of age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. DanubeNeuro will focus on creating innovative drugs, diagnostic methods, disease biomarkers, and imaging techniques. The program is supported by a dedicated fund, Danube BioVentures, and features a rolling application process.
Charles River Laboratories (NYSE: CRL) e CEBINA GmbH hanno annunciato una collaborazione strategica all'interno del programma di accelerazione DanubeNeuro. Questa iniziativa mira a identificare e promuovere progetti di ricerca accademica pionieristici nel campo della neurodegenerazione. La collaborazione sfrutterà l'esperienza di CEBINA nei programmi di accelerazione e l'expertise di Charles River nella scoperta e sviluppo di farmaci per i disturbi del sistema nervoso centrale (SNC).
Il partenariato cerca di affrontare la crescente sfida globale dei disturbi neurodegenerativi legati all'età, come le malattie di Alzheimer e Parkinson. DanubeNeuro si concentrerà sulla creazione di farmaci innovativi, metodi diagnostici, biomarcatori per le malattie e tecniche di imaging. Il programma è sostenuto da un fondo dedicato, Danube BioVentures, e presenta un processo di candidatura continuo.
Charles River Laboratories (NYSE: CRL) y CEBINA GmbH han anunciado una colaboración estratégica dentro del programa de aceleración DanubeNeuro. Esta iniciativa tiene como objetivo identificar y promover proyectos de investigación académica pioneros en el campo de la neurodegeneración. La colaboración aprovechará la experiencia de CEBINA en programas de aceleración y la pericia de Charles River en descubrimiento y desarrollo de fármacos para trastornos del sistema nervioso central (SNC).
La asociación busca abordar el creciente desafío global de los trastornos neurodegenerativos relacionados con la edad, como las enfermedades de Alzheimer y Parkinson. DanubeNeuro se enfocará en crear medicamentos innovadores, métodos de diagnóstico, biomarcadores de enfermedades y técnicas de imagen. El programa cuenta con el apoyo de un fondo dedicado, Danube BioVentures, y presenta un proceso de aplicación continuo.
찰스 리버 랩스(Charles River Laboratories) (NYSE: CRL)와 CEBINA GmbH는 다뉴브신경(DanubeNeuro) 가속화 프로그램 내에서 전략적 협력을 발표했습니다. 이 이니셔티브는 신경퇴행 분야의 혁신적인 학술 연구 프로젝트를 식별하고 발전시키는 것을 목표로 하고 있습니다. 이 협력은 CEBINA의 가속화 프로그램 경험과 중추신경계(CNS) 장애에 대한 찰스 리버의 약물 발견 및 개발 전문성을 활용할 것입니다.
이 파트너십은 알츠하이머와 파킨슨병과 같은 연령 관련 신경퇴행 장애에 대한 글로벌 도전 과제를 해결하려고 합니다. 다뉴브신경은 혁신적인 약물, 진단 방법, 질병 바이오마커 및 이미징 기술 개발에 초점을 맞출 것입니다. 이 프로그램은 전용 기금인 Danube BioVentures의 지원을 받으며 지속적인 신청 과정을 특징으로 합니다.
Charles River Laboratories (NYSE: CRL) et CEBINA GmbH ont annoncé une collaboration stratégique dans le cadre du programme d'accélération DanubeNeuro. Cette initiative vise à identifier et promouvoir des projets de recherche académique novateurs dans le domaine de la neurodégénérescence. La collaboration tirera parti de l'expérience de CEBINA dans les programmes d'accélération et de l'expertise de Charles River en matière de découverte et de développement de médicaments pour les troubles du système nerveux central (SNC).
Le partenariat vise à relever le défi mondial croissant des troubles neurodégénératifs liés à l'âge, tels que les maladies d'Alzheimer et de Parkinson. DanubeNeuro se concentrera sur la création de médicaments innovants, de méthodes de diagnostic, de biomarqueurs de maladies et de techniques d'imagerie. Le programme est soutenu par un fonds dédié, Danube BioVentures, et dispose d'un processus de candidature continu.
Charles River Laboratories (NYSE: CRL) und CEBINA GmbH haben eine strategische Zusammenarbeit im Rahmen des DanubeNeuro-Beschleunigungsprogramms angekündigt. Diese Initiative zielt darauf ab, bahnbrechende akademische Forschungsprojekte im Bereich der Neurodegeneration zu identifizieren und voranzutreiben. Die Kooperation wird CEBINAs Erfahrungen in Beschleunigungsprogrammen und Charles Rivers Fachkenntnisse in der Arzneimittelentdeckung und -entwicklung für Erkrankungen des zentralen Nervensystems (ZNS) nutzen.
Die Partnerschaft verfolgt das Ziel, die wachsende globale Herausforderung von alterungsbedingten neurodegenerativen Erkrankungen wie Alzheimer und Parkinson anzugehen. DanubeNeuro wird sich darauf konzentrieren, innovative Medikamente, diagnostische Verfahren, Biomarker für Erkrankungen und Bildgebungstechniken zu entwickeln. Das Programm wird von einem spezialisierten Fonds, Danube BioVentures, unterstützt und verfügt über ein fortlaufendes Bewerbungsverfahren.
- Strategic collaboration with CEBINA potentially expanding Charles River's presence in neuroscience research
- Access to innovative academic research projects in neurodegenerative diseases through DanubeNeuro program
- Opportunity to contribute to addressing major unmet medical needs in age-related conditions
- None.
This collaboration between Charles River Laboratories and CEBINA marks a significant step forward in neurodegenerative disease research. The partnership leverages Charles River's extensive expertise in CNS drug development and CEBINA's acceleration program capabilities. This synergy could potentially fast-track the development of novel therapies for conditions like Alzheimer's and Parkinson's.
The initiative addresses a critical global health challenge posed by the increasing prevalence of age-related neurodegenerative disorders. By focusing on academic research projects with high potential, the collaboration aims to bridge the gap between innovative ideas and viable drug candidates. This approach could significantly reduce the time and risk associated with bringing new treatments to market, potentially benefiting millions of patients worldwide.
While this collaboration doesn't immediately impact Charles River's financials, it positions the company strategically in the growing neurodegenerative disease market. The global neurodegenerative disease market is projected to reach
Investors should note that this collaboration could lead to long-term revenue growth opportunities for Charles River, particularly if successful therapies emerge from the program. However, drug development in the CNS area is notoriously challenging, with high failure rates. Therefore, while promising, the financial impact of this partnership may not materialize for several years.
As part of the DanubeNeuro program, Charles River and CEBINA will accelerate innovative approaches to treating neurodegenerative diseases
CEBINA’s DanubeNeuro acceleration program identifies and develops pioneering research projects with the potential to create innovative drugs, diagnostic methods, disease biomarkers, and imaging techniques for neurodegenerative diseases. Projects selected for acceleration within DanubeNeuro will benefit from CEBINA’s experience from other acceleration programs, as well as Charles River’s knowledge and extensive expertise in drug discovery and development in the central nervous system (CNS) field. Together, Charles River and CEBINA will enhance this program’s potential to accelerate innovation in neurodegeneration.
"Being part of DanubeNeuro and collaborating with CEBINA aligns perfectly with our commitment to advancing scientific research and innovation," said Aidan Synnott, PhD, Corporate Vice President, Global Discovery Services at Charles River. "We are eager to contribute our expertise to this acceleration program and support the next generation of breakthroughs in neuroscience."
With the trend of increasing lifespan, age-related conditions such as neurodegenerative disorders represent major unmet medical needs globally, carrying significant and growing public health and societal implications. Given the urgent need for novel strategies and approaches to address complex diseases such as Alzheimer’s and Parkinson’s, efforts to accelerate the development of innovative academic ideas into viable drug development programs are imperative.
"We are thrilled to partner with Charles River for our new acceleration program, DanubeNeuro," commented Eszter Nagy, MD, PhD, CEO&CSO of CEBINA. "Charles River’s unparalleled expertise in the development of neurotherapeutics will significantly support us in selection and development process of product candidates. This collaboration will not only bring forth projects with the highest potential, but also de-risks this complex and challenging process for investors. We are prepared to reach our, ultimate goal: improving the lives of patients and their desperate families."
“Since we launched DanubeNeuro 4 months ago, we have been impressed by the quality and quantity of academic research programs with highly innovative propositions and novel, disease modifying approaches to neurodegeneration. By collaborating with Charles River, we are tapping into vast experience and hands-on know-how in CNS drug development that substantially strengthens our initiative to execute drug discovery projects and deliver, high-quality product candidates for further development,” remarked Vanja Nagy, PhD, Scientific Program Director of DanubeNeuro.
DanubeNeuro is supported by a dedicated fund, Danube BioVentures. DanubeNeuro features a rolling application process. Applications can be submitted at danubeneuro.com.
About CEBINA
CEBINA GmbH – Central European Biotech Incubator and Accelerator is an
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917939526/en/
CEBINA Media Contact:
Martina Bellasio, PhD
Senior Business Development Manager
martina.bellasio@cebina.eu
tel: +43 6763731573
www.danubeneuro.com
Charles River Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: Charles River Laboratories International, Inc.
FAQ
What is the purpose of Charles River's collaboration with CEBINA in the DanubeNeuro program?
How will the DanubeNeuro program benefit from Charles River's (CRL) involvement?
What types of projects does the DanubeNeuro program focus on?
How can researchers apply to the DanubeNeuro program involving Charles River (CRL)?
